Enanta Pharma reports topline results from Phase 2a RSV trial

Enanta Pharmaceuticals (NASDAQ:ENTA) reported that, compared with placebo, EDP-938 significantly reduced viral load and resolved clinical symptoms in healthy adults infected with respiratory syncytial virus (RSV).

In the Phase 2a human challenge study of EDP-938, an N-protein inhibitor, 115 subjects were inoculated with RSV. Once infection was confirmed, participants were randomized to receive either 600 mg of EDP-938 once-daily, a 500 mg loading dose followed by a 300 mg twice-daily dose of EDP-938, or placebo, for five days.

EDP-938 administration resulted in a statistically significant reduction in viral load compared with placebo. There was no statistically significant difference between the two EDP-938 dosing groups.

“RSV is a serious unmet medical need with no therapeutic treatment currently available,” Jay Luly, Enanta’s president and CEO, said in a statement.

“Based on today’s positive data for EDP-938, the only N-inhibitor in clinical development, our goal is to initiate our first Phase 2b study by the end of calendar 2019 in adult outpatients with confirmed RSV infections,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.